Study of selinexor, bortezomib, and dexamethasone for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This observational study looks at a three-drug combination (selinexor, bortezomib, and dexamethasone) for people with multiple myeloma that has come back after 1 to 3 prior treatments. It may be an option if you've already tried and not responded to lenalidomide.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with active multiple myeloma
- Your myeloma has returned after 1 to 3 previous treatments
- You have already taken at least one dose of selinexor, bortezomib, and dexamethasone as part of this study (in Italy)
- You have been treated with lenalidomide before and it stopped working
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This early-phase study tests whether selinexor combined with VRd (bortezomib, lenalidomide, and dexamethasone) can improve outcomes for people with high-risk, newly diagnosed multiple myeloma. You may be a candidate if you have certain lab/genetic signs of “high-risk” disease and haven’t had prior myeloma treatment.
This Phase 2 trial studies a treatment called SVRd in people newly diagnosed with multiple myeloma that has spread to areas outside the bone (called extramedullary disease). It aims to see how well the treatment works and whether it is safe for this specific group.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.